NEURODEVELOPMENTAL OUTCOME OF IN UTERO COCAINE EXPOSURE

Project: Research project

Description

The overall objective of this study is to determine the impact of in utero
cocaine exposure upon perinatal outcome and neurodevelopmental consequences
in the infant. The study and control groups will be drawn from an inial
survey population of 2,250 North American black women delivering at the
University of Miami/Jackson Memorial Hospital (UM/)JMH). A detailed
substance abuse history, maternal and infant urine toxicology assays, and
serologic testing for human immunodeficiency virus (HIV-1) will be
performed at delivery. The association between maternal cocaine use and
adverse perinatal outcome, including prematurity, intrauterine growth
retardation, abruptio placenta, and fetal demise will be assessed. A
prospective longitudinal study will be performed to assess neurobehavioral
status, neurodevelopmental outcome and auditory function, of 250 cocaine-
exposed term infants compared to two groups of control term infants. The
first control group (n=125) will include infants unexposed to cocaine but
exposed to alcohol and/or marijuana. The second control group (n=125) will
be drug-free, i.e. unexposed to cocaine, alcohol, or marijuana. Physical
and neurologic examinations will be performed during the delivery
hospitalization and at 1,6,12,18, and 24 months and yearly thereafter. The
Motor Assessment Inventory will be performed at 4 months. Bayley Scales of
Infant Development will be administered at 6,12,18, and 24 months.
Stanford-Binet will be utilized at 3 and 4 years. Auditory brainstem
evoked response (ABR) will be performed at birth with repeat ABR at 1 month
if abnormal. Behavioral audiology assessments will be performed at 1 and 3
years. Echoencephalographic studies will be obtained during the first
postnatal week and at 1 and 6 months postnatal month and at 9 and 21 months
postnatal week and at 1 and 6 months postnatal age. Cranial magnetic
resonance imaging (MRI) will be performed in the first postnatal month and
at 9 and 21 months postnatal age to complement echoencephalography in
detecting parenchymal abnormalities and to delineate myelination patterns
in all infants with abnormal echoencephalograms and in 40 randomly selected
infants without abnormal echoencephalographic findings (20 in the cocaine-
exposed group and 10 in each control group). Serial ABR will also be
performed at 1,4,9, and 21 months in all infants undergoing serial MRI
studies. Future efforts at developing strategies to combat perinatal
cocaine use and minimize its impact upon exposed infants should be enhanced
by the project.
StatusFinished
Effective start/end date4/1/906/30/10

Funding

  • National Institutes of Health: $1,035,577.00
  • National Institutes of Health
  • National Institutes of Health: $65,731.00
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health: $290,758.00
  • National Institutes of Health: $82,642.00
  • National Institutes of Health: $991,289.00
  • National Institutes of Health: $840,187.00
  • National Institutes of Health: $1,035,647.00
  • National Institutes of Health
  • National Institutes of Health: $1,004,997.00
  • National Institutes of Health: $40,421.00
  • National Institutes of Health: $6,566.00
  • National Institutes of Health: $1,038,443.00
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health: $1,100,082.00
  • National Institutes of Health: $1,068,808.00
  • National Institutes of Health
  • National Institutes of Health: $734,555.00
  • National Institutes of Health
  • National Institutes of Health: $149,244.00
  • National Institutes of Health
  • National Institutes of Health

Fingerprint

Cocaine
Control Groups
Caregivers
Mothers
Parturition
Cannabis
HIV-1
Echoencephalography
Risk-Taking
Alcohols
Audiology
Frontal Lobe
Abruptio Placentae
African Americans
Fetal Death
Language
Substance-Related Disorders
Neurologic Examination
Toxicology

ASJC

  • Medicine(all)